Clinical Trial

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-17; most recent amendment 2026-06-29.
Trial Details
NCT Number NCT07192471
Lead Sponsor Kyowa Kirin, Inc.
Conditions T-cell NHL (PTCL or CTCL)
Enrollment 72 participants
Start Date 2026-08
Primary Completion 2029-03 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-01